UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for ulcerative colitis in the United Kingdom. Explore treatment pathways from first-line to advanced biologic therapy.
Ulcerative colitis affects ~146,000 people in the UK. It is a type of inflammatory bowel disease causing inflammation and ulcers in the colon and rectum. Symptoms include bloody diarrhoea, abdominal pain, urgency, and fatigue. It typically follows a relapsing-remitting course. Long-standing UC increases the risk of colorectal cancer, requiring regular colonoscopic surveillance.
Mild-moderate: 5-ASAs (mesalazine) orally and rectally. Moderate: corticosteroids to induce remission, then thiopurines (azathioprine, mercaptopurine) to maintain. Severe: biologics - anti-TNF (infliximab, adalimumab), anti-integrin (vedolizumab), anti-IL-23 (mirikizumab, risankizumab). JAK inhibitors (tofacitinib, upadacitinib) are newer oral options for moderate-severe disease. Treatment target is now mucosal healing, not just symptom control.
Active UK UC trials: next-generation biologics with improved targeting, oral small molecules (S1P receptor modulators), microbiome therapies, precision medicine approaches, and surgical innovations (J-pouch surgery refinements). Crohn's & Colitis UK supports patient access to trials.
Free AI-powered matching - no signup required
Search UC Trials →